MetS is a state of chronic low-grade inflammation evidenced by increased levels of numerous inflammatory biomarkers, e.g., tumor necrosis factor α (TNF-α), interleukin 1β, and C-reactive protein [2,3]. The gene discussed is TNF; the disease is metabolic syndrome.